VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | ZUMA-11 study overview: axi-cel plus utomilumab in R/R DLBCL

Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, gives an overview and update on the ZUMA-11 study of axicabtagene ciloleucel plus utomilumab, an antibody that targets 4-1BB, in patients with refractory diffuse large B-cell lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter